vs
Apellis Pharmaceuticals, Inc.（APLS）与Origin Bancorp, Inc.（OBK）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是Origin Bancorp, Inc.的1.9倍（$199.9M vs $104.0M），Origin Bancorp, Inc.净利率更高（26.6% vs -29.5%，领先56.1%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 3.9%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Origin Bancorp旗下的南方银行是一家社区发展金融机构，总部位于阿肯色州阿卡德尔菲亚。该机构成立于1986年，最初名为南方开发银行公司，常被简称为“南方”，专注服务社区发展相关金融需求。
APLS vs OBK — 直观对比
营收规模更大
APLS
是对方的1.9倍
$104.0M
净利率更高
OBK
高出56.1%
-29.5%
两年增速更快
APLS
近两年复合增速
3.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $104.0M |
| 净利润 | $-59.0M | $27.7M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 26.6% |
| 营收同比 | -5.9% | — |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.89 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSOBK
| Q1 26 | — | $104.0M | ||
| Q4 25 | $199.9M | $103.4M | ||
| Q3 25 | $458.6M | $109.8M | ||
| Q2 25 | $178.5M | $83.5M | ||
| Q1 25 | $166.8M | $94.1M | ||
| Q4 24 | $212.5M | $78.3M | ||
| Q3 24 | $196.8M | $90.8M | ||
| Q2 24 | $199.7M | $96.4M |
净利润APLSOBK
| Q1 26 | — | $27.7M | ||
| Q4 25 | $-59.0M | $29.5M | ||
| Q3 25 | $215.7M | $8.6M | ||
| Q2 25 | $-42.2M | $14.6M | ||
| Q1 25 | $-92.2M | $22.4M | ||
| Q4 24 | $-36.4M | $14.3M | ||
| Q3 24 | $-57.4M | $18.6M | ||
| Q2 24 | $-37.7M | $21.0M |
营业利润率APLSOBK
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 36.2% | ||
| Q3 25 | 48.7% | 10.0% | ||
| Q2 25 | -18.6% | 22.3% | ||
| Q1 25 | -50.0% | 30.4% | ||
| Q4 24 | -12.3% | 23.0% | ||
| Q3 24 | -24.0% | 26.1% | ||
| Q2 24 | -14.7% | 27.7% |
净利率APLSOBK
| Q1 26 | — | 26.6% | ||
| Q4 25 | -29.5% | 28.5% | ||
| Q3 25 | 47.0% | 7.9% | ||
| Q2 25 | -23.6% | 17.5% | ||
| Q1 25 | -55.3% | 23.8% | ||
| Q4 24 | -17.1% | 18.2% | ||
| Q3 24 | -29.2% | 20.5% | ||
| Q2 24 | -18.9% | 21.8% |
每股收益（稀释后）APLSOBK
| Q1 26 | — | $0.89 | ||
| Q4 25 | $-0.40 | $0.95 | ||
| Q3 25 | $1.67 | $0.27 | ||
| Q2 25 | $-0.33 | $0.47 | ||
| Q1 25 | $-0.74 | $0.71 | ||
| Q4 24 | $-0.30 | $0.45 | ||
| Q3 24 | $-0.46 | $0.60 | ||
| Q2 24 | $-0.30 | $0.67 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $1.3B |
| 总资产 | $1.1B | $10.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSOBK
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | $424.2M | ||
| Q3 25 | $479.2M | $626.9M | ||
| Q2 25 | $370.0M | $334.1M | ||
| Q1 25 | $358.4M | $486.2M | ||
| Q4 24 | $411.3M | $470.2M | ||
| Q3 24 | $396.9M | $321.2M | ||
| Q2 24 | $360.1M | $288.1M |
股东权益APLSOBK
| Q1 26 | — | $1.3B | ||
| Q4 25 | $370.1M | $1.2B | ||
| Q3 25 | $401.2M | $1.2B | ||
| Q2 25 | $156.3M | $1.2B | ||
| Q1 25 | $164.2M | $1.2B | ||
| Q4 24 | $228.5M | $1.1B | ||
| Q3 24 | $237.1M | $1.1B | ||
| Q2 24 | $264.3M | $1.1B |
总资产APLSOBK
| Q1 26 | — | $10.2B | ||
| Q4 25 | $1.1B | $9.7B | ||
| Q3 25 | $1.1B | $9.8B | ||
| Q2 25 | $821.4M | $9.7B | ||
| Q1 25 | $807.3M | $9.8B | ||
| Q4 24 | $885.1M | $9.7B | ||
| Q3 24 | $901.9M | $10.0B | ||
| Q2 24 | $904.5M | $9.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSOBK
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $158.9M | ||
| Q3 25 | $108.5M | $59.3M | ||
| Q2 25 | $4.4M | $20.6M | ||
| Q1 25 | $-53.4M | $35.6M | ||
| Q4 24 | $19.4M | $108.5M | ||
| Q3 24 | $34.1M | $39.6M | ||
| Q2 24 | $-8.3M | $11.9M |
自由现金流APLSOBK
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $151.1M | ||
| Q3 25 | $108.3M | $56.8M | ||
| Q2 25 | $4.4M | $19.6M | ||
| Q1 25 | $-53.4M | $34.8M | ||
| Q4 24 | $19.3M | $86.4M | ||
| Q3 24 | — | $32.2M | ||
| Q2 24 | $-8.4M | $6.5M |
自由现金流率APLSOBK
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 146.0% | ||
| Q3 25 | 23.6% | 51.7% | ||
| Q2 25 | 2.5% | 23.5% | ||
| Q1 25 | -32.0% | 37.0% | ||
| Q4 24 | 9.1% | 110.3% | ||
| Q3 24 | — | 35.5% | ||
| Q2 24 | -4.2% | 6.8% |
资本支出强度APLSOBK
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 7.6% | ||
| Q3 25 | 0.0% | 2.3% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.0% | 28.1% | ||
| Q3 24 | 0.0% | 8.1% | ||
| Q2 24 | 0.0% | 5.6% |
现金转化率APLSOBK
| Q1 26 | — | — | ||
| Q4 25 | — | 5.38× | ||
| Q3 25 | 0.50× | 6.88× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.59× | ||
| Q4 24 | — | 7.60× | ||
| Q3 24 | — | 2.13× | ||
| Q2 24 | — | 0.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
